GlassScriptPhysician profile
Matthew S Deich
NPI 1740236249
$3,669.54
in general payments reported to CMS, 2019-2025
22 companies · $920 in 2025
The $920 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $322 · 2021: $689 · 2022: $325 · 2023: $352 · 2024: $637 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,890 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.44 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,230.74 | 2019-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $517.45 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Catalys System |
| Rxsight INC | $439.58 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Alcon Vision LLC | $338.13 | 2019-2025 | Clareon, Luxor |
| Abbvie INC. | $205.80 | 2022-2025 | Alphagan P, Lumigan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $153.62 | 2019-2021 | |
| New World Medical,INC. | $123.02 | 2022-2025 | Via360, Streamline, Kahook Dual Blade |
| Bausch & Lomb Americas INC. | $112.33 | 2022-2025 | Miebo, Vyzulta, Scoutpro Osmolarity System |
| Kala Pharmaceuticals, INC. | $81.82 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $74.04 | 2022 | |
| Aerie Pharmaceuticals, INC. | $67.72 | 2019-2021 | |
| Allergan, INC. | $59.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $47.01 | 2022 | |
| Harrow Eye, LLC | $44.91 | 2024-2025 | Iheezo, Vevye |
| Glaxosmithkline, LLC. | $37.55 | 2020-2023 | Bexsero |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $28.95 | 2024 | Xdemvy |
| Dompe US, INC. | $25.40 | 2024 | Oxervate |
| Glaukos Corporation | $22.50 | 2024 | Istent Infinite Trabecular Micro Bypass System |
| Eyepoint US, INC. | $19.03 | 2022 | |
| Shire North American Group INC | $15.25 | 2019 | |
| Amgen INC. | $14.39 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Deich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.